Skip to main content
Show — Main navigation
Hide — Main navigation
Hair & Scalp
Cutaneous & COVID
AAD VMX 2020
Centers of Excellence
Ligelizumab Receives FDA Breakthrough Therapy Designation
The FDA announced that ligelizumab has received the Breakthrough Therapy designation for the treatment of chronic spontaneous urticaria for patients who have had an inadequate response to H1-antihistamines.
FDA Approves New AK Treatment
The FDA has approved a new topical therapy for the treatment of actinic keratosis on the face or scalp.
FDA Approves Nonprescription Lotion for Treatment of Head Lice
FDA Approves First Topical Androgen Receptor Inhibitor for Acne
The FDA recently approved a new topical treatment that is the first therapy approved in 40 years to target a new mechanism of action for acne.
FDA Approves New Topical Psoriasis Therapy
The FDA has recently approved a new once-daily topical treatment for adult patients with plaque psoriasis.
FDA Approves IL-23 Inhibitor for PsA
The FDA approved guselkumab, a selective IL-23 inhibitor, for the treatment of adult patients with active psoriatic arthritis.
FDA Approves New Topical Rosacea Therapy
The FDA has approved a new topical foam medication for the treatment of inflammatory lesions caused by rosacea in adults.
FDA Approves First Treatment for Photo-Toxic Reactions
The FDA approved a new therapy to increase pain-free light exposure in adult patients with a history of phototoxic reactions caused by erythropoietic protoporphyria.
FDA Approves New Treatment for Facial and Truncal Acne
The FDA recently approved a new topical retinoid for the treatment of acne on both the face and the trunk.
FDA Approves Expanded Indication of Topical Acne Treatment
The FDA approved the expanded indication of topical dapsone 7.5% gel for the treatment of acne vulgaris in patients aged 9 to 11 years.
Stay in the know.
The Dermatologist Newsletter
Back to Top